AI assistants are noticeably more careful with health questions than with almost anything else. They hedge, they qualify, and they cite fewer sources. For medtech brands with real clinical evidence, that caution is an opportunity rather than an obstacle.

Caution rewards the credible

Because models are reluctant to make health claims, they lean heavily on sources they can attribute — peer-reviewed studies, regulatory listings, established medical publishers and institutional pages. Brands whose evidence exists only in a PDF brochure are invisible to that process.

The brands that get cited are the ones whose claims can be traced to something a model recognises as authoritative.

Publish the evidence where it can be found

A clinical trial referenced in a sales deck does nothing for AI visibility. The same trial summarised on an indexable page, with the study named, the sample size stated and a link to the publication, becomes citable. So do regulatory approvals, CE marking details and institutional partnerships.

This is not about publishing more. It is about moving what already exists out of closed formats and into the open web in a structured way.

Answer the questions patients actually ask

Clinical language and patient language diverge sharply. People ask whether something will help their tremor, not whether it modulates peripheral sensory input. Content that bridges the two — using the plain question as the heading and the clinical explanation as the answer — matches how these queries are actually phrased.

Accept slower progress

Health topics move more slowly in AI visibility than consumer categories, because the corroboration bar is higher. That also makes gains more durable once earned.